|
|
Imiquimod |
|
Vaxjo ID |
82 |
|
Vaccine Adjuvant Name |
Imiquimod |
|
Alternative Names |
Aldara™, 1-(2-methypropyl)-IH-imidazo[4,5-c]quinolin-4-amine; R-837; S26308 |
|
Adjuvant VO ID |
VO_0001328
|
|
Description |
Imiquimod (Aldara, 3M) is one of the better characterized imidazoquinolines and is the only one currently approved for clinical use, although only as a topical ointment. It has been demonstrated to possess antiviral and antitumor properties, and it is approved for the treatment of anogenital warts caused by human papillomavirus as well as for basal cell carcinoma and actinic keratosis (Adams et al., 2008). |
|
Stage of Development |
Clinical Trial |
|
Molecular Weight |
240.31 free base |
|
Appearance |
White, fine crystalline solid |
|
Storage |
Solid is stable at room temperature. Shelf life is acceptable (Vogel and Powell, 1995). |
|
Function |
In animal models, imiquimod given either topically or systemically has demonstrated adjuvant activity in vaccines using antigenic peptides, proteins, and DNA, as well as in vaccines using recombinant Listeria or DCs (Adams et al., 2008). |
|
Safety |
Imiquimod's safety package includes extensive evaluation with 4-month dermal and 6-month oral studies completed. In addition, no teratogenic or mutagenic effects were seen (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Adams et al., 2008: Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(1); 776-784. [PubMed: 18566444].
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
